Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures


Last Updated: February 1, 2018; Last Reviewed: February 1, 2018

Non-CMV Herpes: Herpes Simplex, Varicella-Zoster, Human Herpesvirus-8
Member Financial Disclosure
Company Relationship
Durand, Christine Johns Hopkins Gilead Advisory Board
GlaxoSmithKline Research Support
Merck Research Support
ViiV Healthcare Research Support
Gnann, John Medical University of South Carolina BioCryst DSMB Member
GlaxoSmithKline DSMB Member
Merck DSMB Member, Consultant
Holland, Gary University of California, Los Angeles None N/A
Johnston, Christine* University of Washington Aicuris DSMB Member
Genocea Research Support
Novavax Advisory Board
Sanofi Research Support
Vical Research Support
Parsons, Christopher Pardee Hospital, University of North Carolina Health Systems None N/A
Phipps, Warren University of Washington School of Medicine None N/A
Ross, Shannon University of Alabama at Birmingham Merck Advisory Board
Van Wagonar, Nicholas University of Alabama at Birmingham Genocea Research Support
Vical Research Support
Wohl, David University of North Carolina at Chapel Hill Clinical Research Management Research Support
Gilead Research Support, Scientific Advisory Board
Janssen Scientific Advisory Board
ViiV Research Support
*Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from February 1, 2017, through February 1, 2018.

Download Guidelines